This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis (VESTA)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Pierre Fabre Medicament Identifier:
First received: November 7, 2011
Last updated: February 20, 2013
Last verified: February 2013

The primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (OA) over 24 weeks when administered in three weekly injections.

Chondroitin sulfate is one of the components of cartilage. Studies have shown that chondroitin sulphate improves the quality of the hyaluronic acid produced in the joint. The benefit of V0220 combination is based on two main physicochemical properties, in line with the characteristics of osteoarthritic disease: optimising the rheological behaviour and improving the buffering effect on synovial flow ("outflow buffering").

Condition Intervention
Knee Osteoarthritis Device: Chondroitin sulfate and sodium hyaluronate Drug: Hyaluronan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Comparative Study of Efficacy and Safety of Three Intra Articular Injections of V0220 Versus Hyalgan® in Patients Suffering From Symptomatic Knee Osteoarthritis. A Multinational Multicentric, Randomised, Double-blind, Parallel-group Study

Resource links provided by NLM:

Further study details as provided by Pierre Fabre Medicament:

Primary Outcome Measures:
  • Pain relief assessed on a global pain Visual Analogic Scale [ Time Frame: change from baseline over 24 weeks ]

Secondary Outcome Measures:
  • Functional improvement (questionnaire) [ Time Frame: change from baseline over 24 weeks ]
  • Patient's and investigator's global assessment of the disease status (Visual Analogic Scale ) [ Time Frame: change from baseline over 24 weeks ]
  • Patient's health related quality of life (questionnaire) [ Time Frame: over 24 weeks ]
  • Consumption of analgesic medication (paracetamol and NSAIDs)(number of days and quantity) [ Time Frame: over 24 weeks ]
  • Medico-economic questionnaire [ Time Frame: over 24 weeks ]
  • Occurrence of adverse events [ Time Frame: over 24 weeks ]

Enrollment: 0
Arms Assigned Interventions
Experimental: V0220 Device: Chondroitin sulfate and sodium hyaluronate
3 weekly injections
Active Comparator: Hyaluronan Drug: Hyaluronan
3 weekly injections
Other Name: Hyalgan®


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • presenting with uni or bilateral medial and/or lateral femorotibial osteoarthritis of the knee evolving for more than 6 months
  • patients taking analgesic medications for at least 3 months prior to randomisation and dissatisfied with their current therapy

Exclusion Criteria:

  • isolated symptomatic femoropatellar osteoarthritis
  • target knee prothesis
  • having undergone an articular lavage, or an arthroscopy or any surgery on the target knee in the 6 months preceding randomisation,
  • target knee osteoarthritis with clinical joint effusion at selection and at randomization
  • body mass index (BMI) greater than or equal to 30,
  • patient having received any corticosteroid treatment by any administration route (other than inhalers, ocular, auricular route) in the month preceding randomisation,
  • patient having received intra-articular steroid injection in the target knee within the month preceding randomisation or patient having received intra-articular hyaluronic acid in the target knee in the 6 months preceding randomisation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01469507

Sponsors and Collaborators
Pierre Fabre Medicament
Principal Investigator: Emmanuel MAHEU, Dr private practice / unaffiliated
  More Information

Responsible Party: Pierre Fabre Medicament Identifier: NCT01469507     History of Changes
Other Study ID Numbers: V00220 IA 0 01
2011-002295-17 ( EudraCT Number )
Study First Received: November 7, 2011
Last Updated: February 20, 2013

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents processed this record on August 22, 2017